Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Editas Medicine ( (EDIT) ) just unveiled an update.
On June 12, 2025, Editas Medicine announced new in vivo data at the European Hematology Association 2025 Congress, demonstrating significant advancements in gene editing for sickle cell disease and beta thalassemia. The study showed that a single dose of their proprietary targeted lipid nanoparticle (tLNP) in non-human primates achieved a 58% mean on-target editing level in the HBG1/2 promoter region of hematopoietic stem cells, surpassing the therapeutic threshold. This development supports the potential of Editas’ approach to provide a novel treatment for these conditions, with favorable biodistribution and minimal liver targeting, enhancing the company’s position in the gene editing industry.
The most recent analyst rating on (EDIT) stock is a Hold with a $7.00 price target. To see the full list of analyst forecasts on Editas Medicine stock, see the EDIT Stock Forecast page.
Spark’s Take on EDIT Stock
According to Spark, TipRanks’ AI Analyst, EDIT is a Neutral.
Editas Medicine’s strong technical momentum and positive corporate developments in gene editing technologies are significant factors in its stock score. However, financial challenges and speculative valuation limit the score. Investors should consider the high risks associated with the company’s current position.
To see Spark’s full report on EDIT stock, click here.
More about Editas Medicine
Editas Medicine is a pioneering gene editing company focused on utilizing CRISPR/Cas12a and CRISPR/Cas9 genome editing systems to develop in vivo medicines for serious diseases globally. The company aims to discover, develop, manufacture, and commercialize transformative gene editing medicines and holds exclusive licenses for human medicines from Broad Institute and Harvard University.
Average Trading Volume: 1,934,784
Technical Sentiment Signal: Sell
Current Market Cap: $175.8M
For a thorough assessment of EDIT stock, go to TipRanks’ Stock Analysis page.